Kolmar advances biotech push with Woojung Bio deal

Kolmar Holdings, the holding company of Kolmar Korea, is set to acquire control of contract research organization Woojung Bio through a convertible bond deal, as part of a broader push to deepen the group’s foothold in biotechnology research. According to a regulatory filing Thursday, Woojung Bio will issue 35 billion won ($24 million) in convertible bonds to Kolmar Holdings through a third-party allotment, with the bonds maturing on March 3, 2030. If fully converted at 2,325 won per share, the

By The Korea Herald